Yvonne Greenstreet
The International Institute of New England (IINE) has announced Dr. Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals, will be the 2026 recipient of its Golden Door Award. This prestigious award is an annual IINE tradition that honors an individual born outside of the United States who has made outstanding contributions to American society. Dr. Greenstreet exemplifies the drive, innovation, and resilience of immigrants celebrated through the Golden Door Award. She moved to the US in 2004.
Yvonne Greenstreet, MD MBA, OBE, became Chief Executive Officer of Alnylam in January 2022, after serving as the company’s President and Chief Operating Officer from 2020 and as COO from 2016. With more than three decades of leadership in the biopharmaceutical industry, Yvonne has made an enormous impact in enabling the development and delivery of medicines that have improved the lives of people around the world.
Prior to joining Alnylam, Dr. Greenstreet was Senior Vice President and Head of Medicines Development at Pfizer, serving on the executive team leading a rapidly growing $16 billion division. Before that, she worked for 18 years at GlaxoSmithKline plc, where she served as Senior Vice President and Chief Strategy Officer for Research and Development and held various other senior positions.
Born in London and raised in Ghana and the U.K., Yvonne earned a medical degree from the University of Leeds and practiced as a clinician before earning her MBA from INSEAD in Fontainebleau, France, and moving into the biopharmaceutical industry.
Since assuming leadership of Alnylam, she has achieved FDA approval for AMVUTTRA, the first second generation RNAi therapeutic, and has overseen many additional milestones across Alnylam’s clinical pipeline.
Yvonne serves on the board of directors of The American Funds and the Biomedical Sciences Careers Program and is a member of the Council on Foreign Relations.
Dr. Greenstreet was awarded the Order of the British Empire (OBE) in 2025 for services to the biotechnology and life sciences industry. She was recognized as the Healthcare Businesswomen’s Association Woman of Year in 2024 for her contributions to health care and the advancement of women in the workplace.
